Phase 2 Trial of Lintuzumab Ac-225 in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations

Trial Profile

Phase 2 Trial of Lintuzumab Ac-225 in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Lintuzumab Ac-225 (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Dec 2017 New trial record
    • 05 Dec 2017 According Actinium Pharmaceuticals media release, trial initiation is expected in 2018
    • 05 Dec 2017 According Actinium Pharmaceuticals media release, Dr. Gail Roboz, Director of the Leukemia Program and Professor of Medicine at Weill Cornell New-York Presbyterian Hospital, will serve as principal investigator for the trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top